Protective groups in organic chemistry

313 dihalides 309 diols 313 epoxides 312 halohydrins 311 metal complexes 314 mono halides311 Oppenauer oxidation 112, 346 199 Phenolic ethers 157 Grignard...

JFW Mcomie - Plenum Press,

Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives

Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof wherein: A is a bond or --OCH--, where the oxygen is linked to R;

Sher, Philip M，A Mathur - US

Bioreversible carriers in drug design :

Bioreversible carriers in drug design : theory and application edited by Edward B. Roche Pergamon Press, c1987

Roche，B Edward - Pergamon

ML-236B Derivatives and their preparation

Bioreversible carriers in drug design : theory and application edited by Edward B. Roche Pergamon Press, c1987

N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV

The present invention relates to a compound of formula (I) ##STR1## wherein R is substituted adamantyl; and n is 0 to 3; in free form or in acid addition salt form. Compounds of formula I inhibit DPP- IV (dipeptidyl-peptidase-IV) activit...

EB Villhauer - EP

Erythro-(E)-7-[3'-C 1 -3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof

Compounds of the formula ##STR1## wherein R 1 is C 1 -3 alkyl, and Z is ##STR2## wherein R 7 is hydrogen, R 8 or M, wherein R 8 is a physiologically acceptable and hydrolyzable ester group, and M is a pharmaceutically acceptable c...

PL Anderson - US

ML-236B Derivatives and their preparation

Compounds of formula (I): ##STR1## (wherein R represents a group of formula ##STR2## and the corresponding ring-closed lactones, salts (especially alkali metal salts) and esters (especially C.sub.1 -C. sub.5 alkyl esters) thereof may be ...

A Terahara，M Tanaka

Catecholamine surrogates useful as β3 agonists

Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof. These compounds are beta three adrenergic receptor agonists and are useful, therefore for example, in the treatment of diabetes, obesity and gastrointestina...

PTW Cheng，GS Bisacchi，AV Gavai，... - CA

Compounds and compositions as inhibitors of cannabinoid receptor 1 activity

The invention provides compounds having Formula Ia, or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 and Y are as defined in the specification; as well as pharmaceutical compositions comprising such compound...

H Liu，X He，HS Choi，...

Novel thyroid receptor ligands and method

Novel thyroid receptor ligands as provided which have general formula (I) in which: R1 is alkyl of 1 to 4 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 3 carbons or ...

LI YI-LIN，LIU YE，HEDFORS ASA，... - WO